> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music
> Listen on iHeart

After a prolonged funding chill, investors say 2026 is shaping up for continued M&A and dealmaking, and diversified bets beyond oncology and immunology.

Host

⁠Jennifer Smith-Parker⁠, Director of Insights, BioSpace

Guests

⁠Maha Katabi⁠, General Partner, Sofinnova Investments

⁠Andrew Lam⁠, Managing Director, Head of Biotech Private Equity, Ally Bridge Group (ABG)

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.